论文信息 - Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis. - 字舞流文

Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis.

G. Doros | V. Sanchorawala | R. Szalat | Jose Acevedo

[1] M. Dimopoulos,et al. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2] A. Dispenzieri,et al. Systemic immunoglobulin light chain amyloidosis , 2018, Nature Reviews Disease Primers.

[3] P. Milani,et al. Management of the elderly patient with AL amyloidosis. , 2018, European journal of internal medicine.

[4] M. Broder,et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. , 2018, Blood advances.

[5] P. Hawkins,et al. Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis , 2015, Haematologica.

[6] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[7] M. Skinner,et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. , 2004, Blood.